Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication (Ph+ Chronic Myelogenous Leukemia (CML)), By Treatment Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication (Ph+ Chronic Myelogenous Leukemia (CML)), By Treatment Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

Myeloproliferative Disorders Drugs Market Growth & Trends

The global myeloproliferative disorders drugs market size is expected to reach USD 15.83 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Availability of novel drugs, the presence of a strong pipeline, rising incidence of myeloproliferative disorders due to changing lifestyles, growing geriatric population, and increasing public awareness are some of the primary growth stimulants for the market. Therapeutic development in the second-line setting for Jakafi-intolerant patients is estimated to work in favor of the Ph- MPNs market.

Chronic myeloproliferative disorders are rare hematological malignances that involve the abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow. This class of disorder includes four main myeloproliferative diseases, which are further categorized by the presence of the Philadelphia chromosome.

There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group. The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to the presence of a large target population.

Myeloproliferative Disorders Drugs Market Report Highlights

• North America myeloproliferative disorders drugs market dominated the global market with a revenue share of 40.2% in 2024, driven by high prevalence rates of myeloproliferative disorders coupled with advanced healthcare infrastructure that supports innovative treatments.
• Strong unmet needs are likely to shape the future of the market and encourage the development of breakthrough first-in-class therapies. Opportunities remain in the Ph- MPNs setting where there exists an unmet need for a safer drug than Jakafi with higher cure rates and lesser allergic effects
• Some of the key market participants are Novartis, Bristol-Myers Squibb, Pfizer, Takeda, Incyte, and Teva. Primary go-to strategies of prominent players include collaborations for the development and regional expansion in emerging markets.

Please note The report will be delivered in 2-3 business days upon order notification.